Does Pfizer Inc. (PFE)’s Unwinding of Its Stake in Zoetis Inc (ZTS) Offer Value for Either Company’s Shareholders?

Page 1 of 2

Pfizer Inc. (NYSE:PFEsurprised the investment community with the recent announcement that it would attempt to offload the remainder of its stake in veterinary pharmaceutical firm Zoetis Inc (NYSE:ZTS). At minimum, the transaction would be designed to reduce Pfizer’s take in Zoetis to non-majority, non-controlling levels. However, the ultimate goal appears to be the complete liquidation of Pfizer’s interest in its former subsidiary. Although many industry observers expected that this would eventually occur, many have been surprised by the speed and efficacy with which Pfizer appears to be committed to divorcing itself from Zoetis.

Pfizer Inc. (NYSE:PFE)

This transaction could offer a few key advantages for rank-and-file Pfizer investors. On the other hand, it might temporarily impact the earning power of newly minted Zoetis Inc (NYSE:ZTS) shareholders. However, both of these companies are strong and seem well-prepared to handle temporary volatility. Investors who wish to profit from this special situation should start by comparing Pfizer Inc. (NYSE:PFE), Zoetis and other major drug-makers.

Pfizer, Zoetis and the Competition

Pfizer competes with several major pharmaceutical companies as well as a number of smaller, more narrowly focused outfits. Although it does not enjoy much operational overlap, Zoetis Inc (NYSE:ZTS) also competes with major drug-makers by virtue of its size. One of both firms’ closest competitors is Merck & Co., Inc. (NYSE:MRK) .

Pfizer Inc. (NYSE:PFE) and Merck are far larger than Zoetis. At last count, Pfizer’s market capitalization came in at just over $205 billion. Merck enjoyed a market valuation of around $142 billion. Meanwhile, Zoetis reported a comparatively puny valuation of about $16.7 billion. Despite its enormous size, Pfizer is currently the most profitable of these three firms: At 27%, its profit margin is roughly double that of Merck and (NYSE:MRK) exceeds that of Zoetis by a factor of three. Moreover, Pfizer reported an impressive quarterly earnings growth figure of over 50%. With an earnings increase of 26%, Zoetis also appears to be enjoying some profit momentum. By comparison, Merck recently saw its quarterly earnings shrink by a little over 8 percent.

With just slightly more debt than cash and strongly positive cash flow figures, Pfizer and Merck have similar-looking balance sheets. By comparison, Zoetis Inc (NYSE:ZTS)’s financials look slightly weaker: The company has about $3.7 billion in debt to just $468 million in cash. Fortunately, it has an operating cash flow of around $740 million.

How the Deal Is Structured

According to the terms of the deal, all Pfizer Inc. (NYSE:PFE) shareholders are currently eligible to participate in this secondary offering. The offering will be structured as a one-way share swap. As soon as the program begins, individual Pfizer shareholders will be permitted to exchange their holdings for proportional numbers of Zoetis shares. To increase interest in the offering, Pfizer has indicated that shareholders who participate in the deal will earn a premium of between 7 and 8 percent. Although the exact premium will be based on pre-closing trading averages and will not be announced until June 19, it is currently expected to be near 7.5 percent. In other words, Pfizer shareholders who participate in the swap will receive “extra” Zoetis Inc (NYSE:ZTS) shares valued at 7.5 percent of their previous Pfizer holdings.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!